Ainos Inc. (NASDAQ:AIMD) shares traded 22.83% higher at $1.56 on Wall Street last session.
In accordance with the data, 1 analysts cover Ainos Inc. (NASDAQ:AIMD). The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $68.85 and a low of $68.85, we find $68.85. Given the previous closing price of $1.27, this indicates a potential upside of 5321.26 percent. AIMD stock price is now 107.06% away from the 50-day moving average and -42.01% away from the 200-day moving average. The market capitalization of the company currently stands at $32.12M.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
Sponsored
Brokers who have rated the stock have averaged $68.85 as their price target over the next twelve months.
.
A total of 7.70% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in AIMD stock. In total, there are 8 active investors with 0.40% ownership of the company’s stock.
Ainos Inc. (NASDAQ: AIMD) opened at $1.3700 on Thursday. During the past 12 months, Ainos Inc. has had a low of $0.55 and a high of $18.00. As of last week, the company has a debt-to-equity ratio of 0.04, a current ratio of 1.40, and a quick ratio of 1.10. The fifty day moving average price for AIMD is $0.7534 and a two-hundred day moving average price translates $2.7052 for the stock.
The latest earnings results from Ainos Inc. (NASDAQ: AIMD) was released for Sep, 2022. The company reported revenue of $1.76 million for the quarter, compared to $0.36 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 384.3 percent.
Ainos Inc.(AIMD) Company Profile
Ainos, Inc., a healthcare company, engages in the developing medical technologies for point-of-care testing and safe and novel medical treatment for disease indications. The company offers COVID-19 antigen rapid test kit and Ainos’ cloud-based test management App, a cloud-based test management platform comprising an antigen rapid test kit, a personal application, and an enterprise app; COVID-19 nucleic acid test; volatile organic compounds point-of-care testing; Very Low-Dose Oral Interferon Alpha, a low-dose oral interferon alpha formulation based IFN-a’s broad treatment applications; and Synthetic RNA developing a SRNA technology platform in Taiwan. The company was formerly known as Amarillo Biosciences, Inc. and changed its name to Ainos, Inc. in May 2021. Ainos, Inc. was incorporated in 1984 and is based in San Diego, California.
